JP6763083B2 - ラクトバチルス属細菌由来小胞を含む精神疾患の予防または治療用組成物 - Google Patents
ラクトバチルス属細菌由来小胞を含む精神疾患の予防または治療用組成物 Download PDFInfo
- Publication number
- JP6763083B2 JP6763083B2 JP2019508939A JP2019508939A JP6763083B2 JP 6763083 B2 JP6763083 B2 JP 6763083B2 JP 2019508939 A JP2019508939 A JP 2019508939A JP 2019508939 A JP2019508939 A JP 2019508939A JP 6763083 B2 JP6763083 B2 JP 6763083B2
- Authority
- JP
- Japan
- Prior art keywords
- vesicles
- stress
- disorder
- group
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186660 Lactobacillus Species 0.000 title claims description 30
- 208000020016 psychiatric disease Diseases 0.000 title claims description 30
- 239000000203 mixture Substances 0.000 title claims description 29
- 230000002265 prevention Effects 0.000 title claims description 8
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 30
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 30
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 30
- 230000036541 health Effects 0.000 claims description 18
- 235000013376 functional food Nutrition 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 14
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 208000019906 panic disease Diseases 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 description 60
- 230000035882 stress Effects 0.000 description 42
- 241000699666 Mus <mouse, genus> Species 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 18
- 244000199866 Lactobacillus casei Species 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 17
- 230000001430 anti-depressive effect Effects 0.000 description 17
- 230000002180 anti-stress Effects 0.000 description 17
- 235000013958 Lactobacillus casei Nutrition 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 229940017800 lactobacillus casei Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000009227 behaviour therapy Methods 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 230000006399 behavior Effects 0.000 description 10
- 238000010172 mouse model Methods 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 230000009182 swimming Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 230000037326 chronic stress Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000029560 autism spectrum disease Diseases 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000007357 depressive behavior Effects 0.000 description 6
- 201000000980 schizophrenia Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960004801 imipramine Drugs 0.000 description 4
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 235000021109 kimchi Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- -1 etc. Substances 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 206010071368 Psychological trauma Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000012048 forced swim test Methods 0.000 description 1
- 238000001997 free-flow electrophoresis Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000008448 thought Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Description
マウスを利用した実験を通じてラクトバチルスプランタルム由来ナノ小胞を併用投与する場合、ストレスによる憂鬱行動の誘発が遮断されるかを調べようと考えた。このために、図1に示した実験過程によって、7週齢の雄性C57BL/6マウスを購入して、無作為に4個のグループ、すなわち14日間食塩水(0.9% Saline、100μl)を投与した正常マウス群(CONまたはCON+Veh)、ナノ小胞(2ug/mouse/100μl)を投与した正常マウス群(CON+EV)、毎日2時間ずつ14日間身体拘束ストレス(RST)を与えたマウスに食塩水(0.9% Saline、100μl)を投与した群(RST+Veh)、および毎日2時間ずつ14日間身体拘束ストレスを与えたマウスにナノ小胞(EV、2ug/mouse/100μl)を投与した群(RST+EV)に分けて実験を行った後、社会性(Sociability)を測定するU−BOX試験、尾懸垂試験(tail suspension test;TST)および強制水泳試験(forced swim test;FST)を順に進めて、ナノ小胞の投与による抗ストレス効果を評価した。
前記実施例1の結果に加えて、ラクトバチルスプランタルム由来ナノ小胞を投与する場合、慢性ストレスの結果として誘導された憂鬱行動が回復することができるかを評価した。このために、図4の絵で示されたように、7週齢の雄性C57BL/6マウスを購入して、無作為に5個のグループ、すなわち14日間食塩水(0.9% Saline、100μl)を投与した正常マウス群(CON+Veh)、ナノ小胞(EV、2、4、6ug/mouse/100μl)を投与した正常マウス群(CON+EV)、慢性ストレスを与えたマウスに14日間食塩水(0.9% Saline、100μl)を投与した群(RST+Veh)、慢性ストレスを与えたマウスに14日間ナノ小胞(EV、2,4,6 ug/mouse/100μl)を投与した群(RST+EV)、および慢性ストレスを与えたマウスに14日間イミプラミン(IMI、20mg/kg/day)を投与した群(RST+IMI)に分類して実験を行った後、前記実施例1と同様に、それぞれ3種類の憂鬱行動検査を順に実施した。これに加えて、前記1次行動検査(Behavior test−1)後に、2週が経過した後、同じ順に2次行動検査(Behavior test−2)を実施した。また、ナノ小胞投入時に、ナノ小胞は、ストレス処置の終了後から毎日投与するものの、1日(p1)〜4日(p4)までは、2ug/mouse/100μl、5日(p5)〜6日(p6)までは、4ug/mouse/100μl、7日(p7)〜14日(p14)までは、6ug/mouse/100μlに徐々に増加させて投与した。
マウスを利用した実験を通じて、ラクトバチルスカゼイ由来ナノ小胞を併用投与する場合、ストレスによる憂鬱行動の誘発が遮断されるかを調べようと考えた。このために、図9に示した実験過程によって、8週齢の雄性C57BL/6マウスを購入して、無作為に4個のグループ、すなわち14日間食塩水(0.9% Saline、100μl)を投与した正常マウス群(CON+veh)、ナノ小胞(11ug/mouse/100μl)を投与した正常マウス群(CON+Lac)、毎日2時間ずつ14日間身体拘束ストレス(RST)を与えたマウスに食塩水(0.9% Saline、100μl)を投与した群(RST+veh)、および毎日2時間ずつ14日間身体拘束ストレスを与えたマウスにナノ小胞(EV、11ug/mouse/100μl)を投与した群(RST+Lac)に分けて実験を行った後、社会性(Sociability)を測定するU−BOX試験、尾懸垂試験(tail suspension test;TST)および強制水泳試験(forced swim test;FST)をストレス投与2週後およびステレス投与4週後に順に進めて、ナノ小胞の投与による抗ストレス効果および抗うつ病予防効果を評価した。
Claims (11)
- 精神疾患の予防又は治療用である薬学的組成物であって、
ラクトバチルスプランタルム由来小胞を有効量含み、
前記精神疾患が、ストレス、不安障害、外傷後ストレス障害(Post−traumatic Stress Disorder;PTSD)、パニック障害(panic disorder)、及びうつ病(depression)からなる群より選ばれる、薬学的組成物。 - 前記小胞は、平均直径が10nm〜1,000nmであることを特徴とする、請求項1に記載の薬学的組成物。
- 前記小胞は、ラクトバチルスプランタルム培養液から分離することを特徴とする、請求項1又は2に記載の薬学的組成物。
- 前記小胞は、ラクトバチルスプランタルムを添加して製造した食品から分離することを特徴とする、請求項1又は2に記載の薬学的組成物。
- 前記小胞は、ラクトバチルスプランタルムから自然的または人工的に分泌されることを特徴とする、請求項1〜4のいずれか一項に記載の薬学的組成物。
- 精神疾患の改善用健康機能性食品組成物であって、
ラクトバチルスプランタルム由来小胞を有効量含み、
前記精神疾患が、ストレス、不安障害、外傷後ストレス障害(Post−traumatic Stress Disorder;PTSD)、パニック障害(panic disorder)、及びうつ病(depression)からなる群より選ばれる、健康機能性食品組成物。 - 前記小胞は、平均直径が10nm〜1,000nmであることを特徴とする、請求項6に記載の健康機能性食品組成物。
- 前記小胞は、ラクトバチルスプランタルム培養液から分離することを特徴とする請求項6又は7に記載の健康機能性食品組成物。
- 前記小胞は、ラクトバチルスプランタルムを添加して製造した食品から分離することを特徴とする請求項6又は7に記載の健康機能性食品組成物。
- 前記小胞は、ラクトバチルスプランタルムから自然的または人工的に分泌されることを特徴とする請求項6〜9のいずれか一項に記載の健康機能性食品組成物。
- ラクトバチルスプランタルム由来小胞の、精神疾患の予防用または治療用の薬学的組成物又は健康機能性食品組成物の製造のための使用であって、
前記精神疾患が、ストレス、不安障害、外傷後ストレス障害(Post−traumatic Stress Disorder;PTSD)、パニック障害(panic disorder)、及びうつ病(depression)からなる群より選ばれ、前記ラクトバチルスプランタルム由来小胞が、前記薬学的組成物又は健康機能性食品組成物に有効量含まれる、使用。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160103680 | 2016-08-16 | ||
KR10-2016-0103680 | 2016-08-16 | ||
KR10-2017-0085020 | 2017-07-04 | ||
KR1020170085020A KR20180019474A (ko) | 2016-08-16 | 2017-07-04 | 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물 |
KR1020170100459A KR101963957B1 (ko) | 2016-08-16 | 2017-08-08 | 락토바실러스 속 세균 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물 |
KR10-2017-0100459 | 2017-08-08 | ||
PCT/KR2017/008652 WO2018034457A1 (ko) | 2016-08-16 | 2017-08-09 | 락토바실러스 속 세균 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019524835A JP2019524835A (ja) | 2019-09-05 |
JP6763083B2 true JP6763083B2 (ja) | 2020-09-30 |
Family
ID=61531409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019508939A Active JP6763083B2 (ja) | 2016-08-16 | 2017-08-09 | ラクトバチルス属細菌由来小胞を含む精神疾患の予防または治療用組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11583559B2 (ja) |
EP (1) | EP3501527B1 (ja) |
JP (1) | JP6763083B2 (ja) |
KR (2) | KR20180019474A (ja) |
CN (1) | CN109789175B (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102101692B1 (ko) * | 2018-03-05 | 2020-04-20 | 주식회사 엠디헬스케어 | 락토바실러스 속 세균 유래 나노소포 및 이의 용도 |
PL3801061T3 (pl) * | 2018-06-01 | 2023-10-09 | Nzym Deutschland Gmbh | Mikropęcherzyki pochodzące ze sfermentowanych produktów pochodzenia roślinnego, sposób ich przygotowania i zastosowania |
KR101951919B1 (ko) * | 2018-12-07 | 2019-02-25 | (주)에이투젠 | 도파민 분비 증진 기능이 있는 신규한 락토바실러스 루테리 atg-f4 균주, 이를 함유하는 정신질환의 예방 또는 치료용 조성물 |
KR102148707B1 (ko) * | 2019-02-22 | 2020-08-31 | 한국식품연구원 | 우울증 및 불안장애의 예방, 개선 또는 치료 효능을 갖는 김치 유산균 락토바실러스 사케아이 |
WO2020246430A1 (ja) * | 2019-06-03 | 2020-12-10 | アサヒグループホールディングス株式会社 | 歩行能力改善剤 |
EP4070807A1 (en) * | 2019-12-02 | 2022-10-12 | Life Quality Institute, Inc. | Agent for prevention or remediation of stress disorders and composition containing same |
KR102257130B1 (ko) * | 2020-06-16 | 2021-05-28 | 주식회사 엠디헬스케어 | 락토바실러스 파라카세이 유래 소포를 포함하는 신경질환 또는 정신질환 예방 또는 치료용 조성물 |
EP3957316B1 (en) * | 2020-06-16 | 2024-02-07 | MD Healthcare Inc. | Composition for preventing or treating neurological or mental disorders comprising vesicles derived from lactobacillus paracasei |
WO2022015033A1 (ko) * | 2020-07-14 | 2022-01-20 | 주식회사 리스큐어바이오사이언시스 | 페디오코쿠스 이노피나투스 또는 이로부터 유래된 세포밖 소포체를 유효성분으로 포함하는 뇌질환의 치료용 조성물 |
KR20220023301A (ko) | 2020-08-20 | 2022-03-02 | 주식회사 리스큐어바이오사이언시스 | 락토바실러스 사케이 또는 이로부터 유래된 세포밖 소포체를 유효성분으로 포함하는 뇌질환의 치료용 조성물 |
JP2023554271A (ja) * | 2020-12-08 | 2023-12-27 | エムディー ヘルスケア インコーポレイテッド | スフィンゴモナス細菌由来小胞を含む神経疾患または精神疾患の予防または治療用組成物 |
KR102651196B1 (ko) | 2020-12-28 | 2024-03-27 | 주식회사 엠디헬스케어 | 마이크로코커스 루테우스 유래 세포외 소포를 포함하는 안질환 예방 또는 치료용 조성물 |
JP2024501034A (ja) * | 2020-12-28 | 2024-01-10 | エムディー ヘルスケア インコーポレイテッド | マイクロコッカス・ルテウス由来細胞外小胞を含む神経発達疾患、神経疾患、または精神疾患の予防または治療用組成物 |
JP2024520696A (ja) * | 2021-06-03 | 2024-05-24 | エムディー ヘルスケア インコーポレイテッド | ラクトバチルス菌由来細胞外小胞及びその用途 |
EP4349351A1 (en) * | 2021-06-03 | 2024-04-10 | MD Healthcare Inc. | Lactobacillus plantarum-derived vesicle and use thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4065038B2 (ja) | 1996-08-07 | 2008-03-19 | カルピス株式会社 | 計算作業負荷ストレス緩和剤 |
FR2793257B1 (fr) | 1999-05-06 | 2001-07-27 | Gervais Danone Sa | Bacteries lactiques a proprietes anxiolytiques, et leurs utilisations |
NO318426B1 (no) * | 2001-10-02 | 2005-04-18 | Neurozym Biotech As | Et materiale for a senke konsentrasjonen av patogene tarmpeptider |
US20040265279A1 (en) * | 2003-05-08 | 2004-12-30 | Timothy Dinan | Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity |
EP1498144A1 (en) | 2003-07-15 | 2005-01-19 | Universite Pierre Et Marie Curie Paris Vi | Extracellular vesicles from non-pathogenic amoebae useful as vehicle for transferring a molecule of interest to an eukaryotic cell |
SE0400355D0 (sv) | 2004-02-17 | 2004-02-17 | Synbiotics Ab | New synbiotec use |
JP2008081434A (ja) * | 2006-09-27 | 2008-04-10 | Univ Of Miyazaki | 気分改善剤 |
WO2008155998A1 (ja) * | 2007-06-21 | 2008-12-24 | Nagase & Co., Ltd. | 抗不安抗うつ剤 |
KR100942290B1 (ko) | 2007-10-25 | 2010-02-16 | 두두원발효(주) | 김치유산균으로 발효한 콩 요구르트를 유효성분으로함유하는 우울증 예방 및 치료용 조성물 |
US8669267B2 (en) | 2008-08-21 | 2014-03-11 | Suntory Holdings Limited | Pharmaceutical, food or beverage having inhibitory activity on serotonin transporter |
MX2011004142A (es) * | 2008-11-03 | 2011-05-25 | Nestec Sa | Una composicion nutricional que comprende probioticos y que mejora los patrones de sueño. |
WO2011027956A2 (ko) * | 2009-09-04 | 2011-03-10 | 주식회사이언메딕스 | 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델 |
JP5592640B2 (ja) | 2009-11-30 | 2014-09-17 | アピ株式会社 | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤 |
KR20110082480A (ko) * | 2010-01-11 | 2011-07-19 | 포항공과대학교 산학협력단 | 포유동물 체내에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도 |
SG191420A1 (en) | 2010-12-29 | 2013-07-31 | Nestec Sa | Fiber and probiotics for reducing intestinal symptoms related to chronic stress |
EP2833911A4 (en) * | 2012-04-06 | 2016-07-13 | Univ Cornell | SUB-VACCINE VACCINATING PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES |
JP6329125B2 (ja) * | 2013-02-27 | 2018-05-23 | 株式会社明治 | ストレス軽減剤 |
CN103550778B (zh) | 2013-11-18 | 2015-12-30 | 四川科瑞德制药有限公司 | 一种治疗情感性精神障碍疾病的药物组合物 |
PL2937424T3 (pl) * | 2014-04-23 | 2017-09-29 | National Yang-Ming University | Bakteria kwasu mlekowego, kompozycja ją zawierająca i ich zastosowanie |
SG11201703193XA (en) * | 2014-10-28 | 2017-05-30 | Medlab Ip Pty Ltd | Treatment for depression and depressive disorders |
CR20170355A (es) | 2015-02-03 | 2018-02-20 | Winclove Holding B V | Composición probiótica que comprende al menos bifidobacterium bifidum w23 y es capaz de controlar la función de la barrera intestinal |
KR20160110232A (ko) * | 2015-03-11 | 2016-09-21 | 주식회사 엠디헬스케어 | 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물 |
JP6654639B2 (ja) * | 2015-09-18 | 2020-02-26 | 国立大学法人徳島大学 | 血中トリプトファン濃度上昇抑制剤 |
KR102394638B1 (ko) * | 2015-09-30 | 2022-05-09 | (주)아모레퍼시픽 | 유산균 유래의 세포외 소낭을 포함하는 탈모 방지 또는 육모 촉진용 조성물 |
-
2017
- 2017-07-04 KR KR1020170085020A patent/KR20180019474A/ko active Search and Examination
- 2017-08-08 KR KR1020170100459A patent/KR101963957B1/ko active IP Right Grant
- 2017-08-09 EP EP17841640.0A patent/EP3501527B1/en active Active
- 2017-08-09 JP JP2019508939A patent/JP6763083B2/ja active Active
- 2017-08-09 US US16/325,884 patent/US11583559B2/en active Active
- 2017-08-09 CN CN201780050397.7A patent/CN109789175B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
US11583559B2 (en) | 2023-02-21 |
EP3501527B1 (en) | 2024-03-06 |
KR20180019482A (ko) | 2018-02-26 |
EP3501527A1 (en) | 2019-06-26 |
EP3501527A4 (en) | 2020-05-06 |
KR101963957B1 (ko) | 2019-03-29 |
CN109789175A (zh) | 2019-05-21 |
EP3501527C0 (en) | 2024-03-06 |
CN109789175B (zh) | 2022-07-26 |
JP2019524835A (ja) | 2019-09-05 |
KR20180019474A (ko) | 2018-02-26 |
US20190209628A1 (en) | 2019-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6763083B2 (ja) | ラクトバチルス属細菌由来小胞を含む精神疾患の予防または治療用組成物 | |
KR102085787B1 (ko) | 바실러스 속 세균 유래 나노소포 및 이의 용도 | |
TWI787272B (zh) | 包含細菌菌株之組合物 | |
JP2011504884A (ja) | うつおよび不安の治療のための医薬組成物 | |
US20200121756A1 (en) | Compositions comprising bacterial strains | |
WO2018034430A1 (ko) | 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물 | |
JP2022520904A (ja) | うつ病及び不安障害の予防、改善又は治療効能を有するキムチ乳酸菌ラクトバチルスサケイ | |
WO2018034457A1 (ko) | 락토바실러스 속 세균 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물 | |
JP2008137941A (ja) | 睡眠改善用組成物 | |
JP2021138776A (ja) | 下痢型過敏性腸症候群抑制剤及び食品組成物 | |
JP2013063941A (ja) | 過敏性腸症候群の予防又は改善剤 | |
CN114642684B (zh) | 用于防治焦虑抑郁症的直肠真杆菌(Eubacterium rectale) | |
JPWO2018221627A1 (ja) | スベリヒユ処理物、スベリヒユ処理物の製造方法、サプリメント、医薬品、腸管粘膜保護剤及び整腸剤 | |
KR102124794B1 (ko) | 지오바실러스 속 세균 유래 나노소포 및 이의 용도 | |
KR20220119055A (ko) | 박테리아 균주를 포함하는 조성물 | |
KR20240040089A (ko) | 보상 조절 장애의 방지 및/또는 치료 | |
US20210002701A1 (en) | Nanovesicles derived from rhizobium sp. bacteria, and use thereof | |
KR20240113658A (ko) | 락토바실러스 람노서스 jy02 균주의 세포 추출액 및 배양액을 포함하는 근육질환 예방, 개선 또는 치료용 조성물 | |
TW202135842A (zh) | 包含細菌品系之組合物 | |
WO2023001368A1 (en) | Prevention and/or treatment of reward dysregulation disorders | |
TW202128199A (zh) | 包含細菌品系之組合物 | |
JP2019116468A (ja) | オゴノリ科植物の水抽出物またはその発酵体の使用、ならびに神経疾患を治療および/または緩和する医薬組成物および/または健康食品 | |
JP2021515557A (ja) | エンヒドロバクター細菌由来のナノ小胞及びその用途 | |
NZ760637B2 (en) | Compositions comprising bacterial strains |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190225 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200327 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200818 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200909 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6763083 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |